Shopping Cart
- Remove All
Your shopping cart is currently empty
Olomoucine is an ATP-competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3, and 25 µM, respectively. It regulates the cell cycle and exhibits anti-melanin tumor activities.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $60 | In Stock | |
| 5 mg | $147 | In Stock | |
| 10 mg | $239 | In Stock | |
| 25 mg | $479 | In Stock | |
| 50 mg | $698 | In Stock | |
| 100 mg | $892 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $138 | In Stock |
| Description | Olomoucine is an ATP-competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3, and 25 µM, respectively. It regulates the cell cycle and exhibits anti-melanin tumor activities. |
| Targets&IC50 | CDK5-p35:25 μM, CDK2-CyclinE:7 μM, CDK2-CyclinA:7 μM |
| In vitro | In Rdditapes oocytes, Olomoucine (0-150 μM) inhibits prophase/metaphase transition. In CTLL-2 cells, Olomoucine (0-1000 μM) inhibits DNA synthesis and triggers a Gl arrest similar to interleukin-2 deprivation. In NSCLC MB65 cells, Olomoucine (0-100 μM) inhibits Gl/S transition[1]. Olomoucine inhibits tumor cell survival with IC50s of 32.35, 42.15, and 82.30 μM for dog, mouse B16, and human melanoma, respectively[4]. |
| In vivo | In female Balb C− mice, Olomoucine results faster plasma concentration decreasing with 50 mg/kg (as single agent) than 16.6 mg/kg (as cassette)[3]. In dog with spontaneous melanoma, Olomoucine (8 mg/kg; i.v.) induces programmed cell death of cancer cells and results in rapid eradication of at least 68% of the tumor cells without side effects[4]. |
| Molecular Weight | 298.34 |
| Formula | C15H18N6O |
| Cas No. | 101622-51-9 |
| Smiles | Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12 |
| Relative Density. | 1.36 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (167.59 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.